About

Overview

Abcentra develops oxidized LDL blocking therapeutics to treat cardiovascular inflammation

Many patients worldwide live with substantial risk of a major cardiovascular event because of chronic inflammation.  This includes patients who have recently had a heart attack, and patients with calcific aortic valve disease.  It also includes patients with chronic inflammatory diseases such as psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE).

Abcentra is developing a potential solution for patients with cardiovascular inflammation – therapeutics that target oxidized low-density lipoprotein (LDL). Oxidized LDL is a well-described pro-inflammatory mediator that is strongly implicated in atherosclerotic cardiovascular disease, type 2 diabetes, calcific aortic valve disease and several inflammatory diseases. Oxidized LDL blockade offers a promising new way to treat cardiovascular inflammation and meet large unmet medical needs in cardiovascular disease.

Our pipeline focuses on developing oxLDL-blocking therapeutics for patients who have significant residual risk of major a cardiovascular event from chronic inflammation (see Pipeline).  Our lead candidate, orticumab, is a fully-human, first-in-class antibody that targets a specific oxidized LDL epitope. Orticumab is currently in phase 2 in psoriasis patients with cardiometabolic risk factors.  Several additional indications are also being pursued.

Abcentra has offices in Los Angeles. The Company’s ownership includes world-renowned Los Angeles hospital, Cedar-Sinai.  Our team includes experienced drug developers and founding scientists that pioneered our approach to oxidized LDL blockade.

Management

kevin b bacon
Prediman K. Shah, M.D.
Jan Nilsson, M.D., PhD
Chris Farina, MS, RAC
Ryan Abbott, M.D., J.D.

Board of Directors

JOHN FARINA

Managing Director, Glenbarr Partners

WILLEM MESDAG

Managing Director, Red Mountain Capital

EDWARD M. PRUNCHUNAS

Chief Financial Officer, Cedars-Sinai Medical Center

PREDIMAN K. SHAH, M.D.

Director and Founder, Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center

JAN NILSSON, M.D., PHD

Chairman, Clinical Research Center, Lund University

TIMOTHY WRIGHT, M.D.

General Partner, Time Bioventures

Strategic Advisers

D.A. WALLACH

KARAN BILIMORIA

Investors

Our Pipeline

Our pipeline focuses on patient populations at high-risk of cardiometabolic complications from underlying chronic inflammation.